John. J. Treanor

Q: What Schools Are Affiliated With John. J. Treanor

John. J. Treanor is affiliated with the following schools: Eastern Virginia Medical School, University of Pittsburgh, University of Rochester

John. J. Treanor's AcademicInfluence.com Rankings

John. J. Treanor

Philosophy

#8773

World Rank

#12217

Historical Rank

Logic

#5791

World Rank

#7230

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Why Is John. J. Treanor Influential?

(Suggest an Edit or Addition)

(See a Problem?)

John. J. Treanor's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Efficacy and Safety of the Oral Neuraminidase Inhibitor Oseltamivir in Treating Acute Influenza (2000) (916)
The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children. (1998) (913)
Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. (2006) (713)
Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections (1997) (668)
Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment. (1999) (562)
Loneliness, social network size, and immune response to influenza vaccination in college freshmen. (2005) (529)
Influenza (2018) (502)
Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine. (2000) (435)
Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine. (2000) (394)
Efficacy of an acellular pertussis vaccine among adolescents and adults. (2005) (393)
Contemporary H3N2 influenza viruses have a glycosylation site that alters binding of antibodies elicited by egg-adapted vaccine strains (2017) (389)
Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group. (2000) (350)
Randomized, double-blind controlled phase 3 trial comparing the immunogenicity of high-dose and standard-dose influenza vaccine in adults 65 years of age and older. (2009) (344)
Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans. (2001) (338)
Safety and efficacy of the neuraminidase inhibitor GG167 in experimental human influenza. (1996) (288)
Cross-Reactive Neuraminidase Antibodies Afford Partial Protection against H5N1 in Mice and Are Present in Unexposed Humans (2007) (280)
Positive Emotional Style Predicts Resistance to Illness After Experimental Exposure to Rhinovirus or Influenza A Virus (2006) (279)
Mercury concentrations and metabolism in infants receiving vaccines containing thiomersal: a descriptive study (2002) (275)
Objective and subjective socioeconomic status and susceptibility to the common cold. (2008) (272)
Recovery of drug-resistant influenza virus from immunocompromised patients: a case series. (2006) (258)
Cellular and Humoral Immunity following Snow Mountain Virus Challenge (2005) (257)
Clinical responses to undiluted and diluted smallpox vaccine. (2002) (249)
Evaluation of trivalent, live, cold-adapted (CAIV-T) and inactivated (TIV) influenza vaccines in prevention of virus infection and illness following challenge of adults with wild-type influenza A (H1N1), A (H3N2), and B viruses. (1999) (249)
Influenza vaccine--outmaneuvering antigenic shift and drift. (2004) (248)
Half- vs full-dose trivalent inactivated influenza vaccine (2004-2005): age, dose, and sex effects on immune responses. (2008) (246)
Effectiveness of seasonal influenza vaccines in the United States during a season with circulation of all three vaccine strains. (2012) (246)
Influenza Infection in Humans Induces Broadly Cross-Reactive and Protective Neuraminidase-Reactive Antibodies (2018) (243)
Passively transferred monoclonal antibody to the M2 protein inhibits influenza A virus replication in mice (1990) (241)
Vaccines for seasonal and pandemic influenza. (2006) (239)
Norovirus vaccine against experimental human GII.4 virus illness: a challenge study in healthy adults. (2015) (223)
Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. GG167 Influenza Study Group. (1997) (221)
Both Neutralizing and Non-Neutralizing Human H7N9 Influenza Vaccine-Induced Monoclonal Antibodies Confer Protection. (2016) (214)
Viral Respiratory Infections in the Institutionalized Elderly: Clinical and Epidemiologic Findings (1992) (211)
Adjuvanted intranasal Norwalk virus-like particle vaccine elicits antibodies and antibody-secreting cells that express homing receptors for mucosal and peripheral lymphoid tissues. (2010) (205)
Maternal immunisation with trivalent inactivated influenza vaccine for prevention of influenza in infants in Mali: a prospective, active-controlled, observer-blind, randomised phase 4 trial (2016) (192)
The development of multivalent bovine rotavirus (strain WC3) reassortant vaccine for infants. (1996) (189)
Simulation and Prediction of the Adaptive Immune Response to Influenza A Virus Infection (2009) (176)
Safety and immunogenicity of a baculovirus-expressed hemagglutinin influenza vaccine: a randomized controlled trial. (2007) (170)
Psychological Stress and Antibody Response to Influenza Vaccination: When Is the Critical Period for Stress, and How Does It Get Inside the Body? (2004) (167)
Expression, self-assembly, and antigenicity of a snow mountain agent-like calicivirus capsid protein (1995) (164)
Immune responses and antibody decay after immunization of adolescents and adults with an acellular pertussis vaccine: the APERT Study. (2004) (162)
Safety, efficacy, and immunogenicity of a live, quadrivalent human-bovine reassortant rotavirus vaccine in healthy infants. (2004) (156)
Protective efficacy of combined live intranasal and inactivated influenza A virus vaccines in the elderly. (1992) (155)
Differential effects of pneumococcal vaccines against serotypes 6A and 6C. (2008) (154)
Protective efficacy of a trivalent recombinant hemagglutinin protein vaccine (FluBlok®) against influenza in healthy adults: a randomized, placebo-controlled trial. (2011) (149)
H3N2 Influenza Virus Infection Induces Broadly Reactive Hemagglutinin Stalk Antibodies in Humans and Mice (2013) (145)
Influence of initial vaccination with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine on anti-pneumococcal responses following subsequent pneumococcal vaccination in adults 50 years and older. (2013) (141)
Kupffer cell-dependent hepatitis occurs during influenza infection. (2006) (140)
Induction of a potent immune response in the elderly using the TLR-5 agonist, flagellin, with a recombinant hemagglutinin influenza-flagellin fusion vaccine (VAX125, STF2.HA1 SI). (2011) (139)
Safety and immunogenicity of an oral, replicating adenovirus serotype 4 vector vaccine for H5N1 influenza: a randomised, double-blind, placebo-controlled, phase 1 study (2013) (137)
Comparison of the safety, vaccine virus shedding, and immunogenicity of influenza virus vaccine, trivalent, types A and B, live cold-adapted, administered to human immunodeficiency virus (HIV)-infected and non-HIV-infected adults. (2000) (131)
Safety and immunogenicity of a recombinant hemagglutinin influenza-flagellin fusion vaccine (VAX125) in healthy young adults. (2010) (130)
The B allele of the NS gene of avian influenza viruses, but not the A allele, attenuates a human influenza A virus for squirrel monkeys. (1989) (127)
Comparison of Quantitative Reverse Transcription-PCR to Viral Culture for Assessment of Respiratory Syncytial Virus Shedding (2003) (126)
Bordetella Pertussis infections in vaccinated and unvaccinated adolescents and adults, as assessed in a national prospective randomized Acellular Pertussis Vaccine Trial (APERT). (2006) (124)
Development of VAX128, a recombinant hemagglutinin (HA) influenza-flagellin fusion vaccine with improved safety and immune response. (2012) (121)
FluBlok, a recombinant hemagglutinin influenza vaccine (2008) (120)
A novel intramuscular bivalent norovirus virus-like particle vaccine candidate--reactogenicity, safety, and immunogenicity in a phase 1 trial in healthy adults. (2014) (120)
Phase 1 Trial of AMA1-C1/Alhydrogel plus CPG 7909: An Asexual Blood-Stage Vaccine for Plasmodium falciparum Malaria (2008) (117)
Effectiveness of Non-Adjuvanted Pandemic Influenza A Vaccines for Preventing Pandemic Influenza Acute Respiratory Illness Visits in 4 U.S. Communities (2011) (116)
Comparison of pneumococcal polysaccharide and CRM197-conjugated pneumococcal oligosaccharide vaccines in young and elderly adults (1997) (115)
Dose-related safety and immunogenicity of a trivalent baculovirus-expressed influenza-virus hemagglutinin vaccine in elderly adults. (2006) (115)
Acute Respiratory Tract Infection in Daycare Centers for Older Persons (1995) (115)
Efficacy and Tolerability of the Oral Neuraminidase Inhibitor Peramivir in Experimental Human Influenza: Randomized, Controlled Trials for Prophylaxis and Treatment (2005) (113)
Effects of influenza vaccination in HIV-infected adults: a double-blind, placebo-controlled trial. (1998) (112)
Influenza A virus vaccines containing purified recombinant H3 hemagglutinin are well tolerated and induce protective immune responses in healthy adults. (1995) (109)
The Cutter Incident: How America’s First Polio Vaccine Led to the Growing Vaccine Crisis (2006) (106)
Serological Correlates of Protection against a GII.4 Norovirus (2015) (102)
Human calicivirus genogroup II capsid sequence diversity revealed by analyses of the prototype Snow Mountain agent (1997) (102)
Safety and immunogenicity of a trivalent, inactivated, mammalian cell culture-derived influenza vaccine in healthy adults, seniors, and children. (2002) (101)
The interferon antagonist NS2 protein of respiratory syncytial virus is an important virulence determinant for humans. (2006) (99)
Safety, efficacy, and immunogenicity of an inactivated influenza vaccine in healthy adults: a randomized, placebo-controlled trial over two influenza seasons (2010) (98)
Influenza Virus Vaccination Elicits Poorly Adapted B Cell Responses in Elderly Individuals. (2019) (98)
Expression and self-assembly of recombinant capsid protein from the antigenically distinct Hawaii human calicivirus (1997) (95)
Chronic stress in nonelderly caregivers: psychological, endocrine and immune implications. (2002) (94)
Immune responses of healthy subjects to a single dose of intramuscular inactivated influenza A/Vietnam/1203/2004 (H5N1) vaccine after priming with an antigenic variant. (2006) (93)
Evaluation of a recombinant hemagglutinin expressed in insect cells as an influenza vaccine in young and elderly adults. (1996) (87)
Evaluation of live attenuated influenza vaccines in children 6-18 months of age: safety, immunogenicity, and efficacy. National Institute of Allergy and Infectious Diseases, Vaccine and Treatment Evaluation Program and the Wyeth-Ayerst ca Influenza Vaccine Investigators Group. (1996) (87)
Respiratory viral infections in the elderly (1999) (87)
The TLR9 Ligand CpG Promotes the Acquisition of Plasmodium falciparum-Specific Memory B Cells in Malaria-Naive Individuals1 (2009) (86)
Subclass-specific serum antibody responses to recombinant Norwalk virus capsid antigen (rNV) in adults infected with Norwalk, Snow Mountain, or Hawaii virus (1993) (86)
Genomics reveals historic and contemporary transmission dynamics of a bacterial disease among wildlife and livestock (2016) (85)
Influenza Viruses, Including Avian Influenza and Swine Influenza (2010) (85)
Experimental infection of humans with A2 respiratory syncytial virus. (2004) (84)
Generation and Protective Ability of Influenza Virus-Specific Antibody-Dependent Cellular Cytotoxicity in Humans Elicited by Vaccination, Natural Infection, and Experimental Challenge. (2016) (83)
Development of an ELISA to detect MX virus, a human calicivirus in the snow Mountain agent genogroup. (1995) (82)
Safety and immunogenicity of an inactivated influenza A/H5N1 vaccine given with or without aluminum hydroxide to healthy adults: results of a phase I-II randomized clinical trial. (2008) (81)
Seasonal Effectiveness of Live Attenuated and Inactivated Influenza Vaccine (2016) (80)
Recombinant baculovirus influenza A hemagglutinin vaccines are well tolerated and immunogenic in healthy adults. (1996) (78)
Decreased influenza-specific B cell responses in rheumatoid arthritis patients treated with anti-tumor necrosis factor (2011) (78)
Safety of the trivalent, cold-adapted influenza vaccine in preschool-aged children. (2002) (78)
Immune correlates of protection against influenza in the human challenge model. (2003) (76)
Intranasal administration of a proteosome-influenza vaccine is well-tolerated and induces serum and nasal secretion influenza antibodies in healthy human subjects. (2006) (75)
Evaluation of safety and immunogenicity of recombinant influenza hemagglutinin (H5/Indonesia/05/2005) formulated with and without a stable oil-in-water emulsion containing glucopyranosyl-lipid A (SE+GLA) adjuvant. (2013) (75)
Mercury Levels in Newborns and Infants After Receipt of Thimerosal-Containing Vaccines (2008) (75)
CD4+ T-Cell Expansion Predicts Neutralizing Antibody Responses to Monovalent, Inactivated 2009 Pandemic Influenza A(H1N1) Virus Subtype H1N1 Vaccine (2012) (70)
Live attenuated H7N7 influenza vaccine primes for a vigorous antibody response to inactivated H7N7 influenza vaccine. (2014) (68)
Characterization of pneumococcal specific antibodies in healthy unvaccinated adults. (1998) (68)
B Cell Response and Hemagglutinin Stalk-Reactive Antibody Production in Different Age Cohorts following 2009 H1N1 Influenza Virus Vaccination (2013) (68)
Evaluation of a single dose of half strength inactivated influenza vaccine in healthy adults. (2002) (65)
Safety and immunogenicity of a subvirion inactivated influenza A/H5N1 vaccine with or without aluminum hydroxide among healthy elderly adults. (2009) (63)
Comparison of the immunogenicity and safety of a split-virion, inactivated, trivalent influenza vaccine (Fluzone®) administered by intradermal and intramuscular route in healthy adults. (2011) (62)
Infection-induced proinflammatory cytokines are associated with decreases in positive affect, but not increases in negative affect (2007) (62)
Effect of yearly vaccinations with live, attenuated, cold-adapted, trivalent, intranasal influenza vaccines on antibody responses in children (2003) (61)
CLINICAL PRACTICE. Influenza Vaccination. (2016) (61)
Divergent H7 Immunogens Offer Protection from H7N9 Virus Challenge (2014) (59)
Economic impact of pertussis. (1997) (59)
Effects of the neuraminidase inhibitor zanamavir on otologic manifestations of experimental human influenza. (1997) (58)
Repeat vaccination reduces antibody affinity maturation across different influenza vaccine platforms in humans (2019) (57)
Management of Yellowstone bison and brucellosis transmission risk – Implications for conservation and restoration (2011) (57)
Antigenic relatedness among the Norwalk‐like agents by serum antibody rises (1990) (56)
Recommended adult immunization schedule: United States, October 2007-September 2008 (2007) (55)
Evaluation of the safety and immunogenicity of a booster (third) dose of inactivated subvirion H5N1 influenza vaccine in humans. (2008) (55)
Comparative Study of Influenza Virus Replication in MDCK Cells and in Primary Cells Derived from Adenoids and Airway Epithelium (2012) (55)
Novel agents of viral enteritis in humans. (1987) (55)
Comparative immunogenicity of recombinant influenza hemagglutinin (rHA) and trivalent inactivated vaccine (TIV) among persons > or =65 years old. (2009) (52)
Effect of simultaneous administration of cold-adapted and wild-type influenza A viruses on experimental wild-type influenza infection in humans (1994) (52)
Evaluation of the protective efficacy of a serotype 1 bovine-human rotavirus reassortant vaccine in infants. (1995) (51)
Broad Hemagglutinin-Specific Memory B Cell Expansion by Seasonal Influenza Virus Infection Reflects Early-Life Imprinting and Adaptation to the Infecting Virus (2019) (51)
Live attenuated and inactivated influenza vaccines in children. (2015) (49)
Effect of Influenza A(H5N1) Vaccine Prepandemic Priming on CD4+ T-Cell Responses (2014) (47)
Characterization of the Snow Mountain agent of viral gastroenteritis (1986) (47)
Enzyme-linked immunosorbent assays for Snow Mountain and Norwalk agents of viral gastroenteritis (1986) (46)
Weathering the influenza vaccine crisis. (2004) (45)
Oral LY217896 for prevention of experimental influenza A virus infection and illness in humans (1994) (44)
The attenuation phenotype conferred by the M gene of the influenza A/Ann Arbor/6/60 cold-adapted virus (H2N2) on the A/Korea/82 (H3N2) reassortant virus results from a gene constellation effect. (1992) (44)
State‐space modeling to support management of brucellosis in the Yellowstone bison population (2015) (43)
A Highly Potent and Broadly Neutralizing H1 Influenza-Specific Human Monoclonal Antibody (2018) (43)
High-Affinity H7 Head and Stalk Domain-Specific Antibody Responses to an Inactivated Influenza H7N7 Vaccine After Priming With Live Attenuated Influenza Vaccine. (2015) (43)
WC3 reassortant vaccines in children. (1996) (43)
Evaluation of the Safety and Immunogenicity of a Candidate Pandemic Live Attenuated Influenza Vaccine (pLAIV) Against Influenza A(H7N9) (2015) (42)
Molecular genetics of psychopathologies: A search for simple answers to complex problems (1996) (41)
Immunogenicity, safety and consistency of new trivalent inactivated influenza vaccine. (2008) (41)
CD8+ T cell immunity to 2009 pandemic and seasonal H1N1 influenza viruses. (2011) (41)
Robust mucosal-homing antibody-secreting B cell responses induced by intramuscular administration of adjuvanted bivalent human norovirus-like particle vaccine. (2015) (41)
Detection of intracellular antigen-specific cytokines in human T cell populations. (1999) (40)
Clinical Benefits with Oseltamivir in Treating Influenza in Adult Populations (2003) (40)
Vaccination with a Recombinant H7 Hemagglutinin-Based Influenza Virus Vaccine Induces Broadly Reactive Antibodies in Humans (2017) (38)
Psychosocial Factors and the Response to Influenza Vaccination in Older Adults (2004) (38)
Intranasally administered interferon as prophylaxis against experimentally induced influenza A virus infection in humans. (1987) (38)
Evaluation of live, cold-adapted influenza A and B virus vaccines in elderly and high-risk subjects. (1998) (37)
Evaluation of a pentavalent conjugated pneumococcal vaccine in toddlers. (1997) (37)
Evaluation of the genetic stability of the temperature-sensitive PB2 gene mutation of the influenza A/Ann Arbor/6/60 cold-adapted vaccine virus (1994) (37)
Influence of Birth Cohort on Effectiveness of 2015–2016 Influenza Vaccine Against Medically Attended Illness Due to 2009 Pandemic Influenza A(H1N1) Virus in the United States (2018) (37)
Approaches to improved influenza vaccination. (2000) (37)
Cryptococcal peritonitis: report of a case developing during continuous ambulatory peritoneal dialysis and review of the literature. (1993) (36)
Predicting Bison Migration out of Yellowstone National Park Using Bayesian Models (2011) (36)
Evaluation of cold-adapted, reassortant influenza B virus vaccines in elderly and chronically ill adults. (1994) (36)
Correlates of Immunity to Influenza as Determined by Challenge of Children with Live, Attenuated Influenza Vaccine (2016) (34)
Vaccination strategies for managing brucellosis in Yellowstone bison. (2010) (34)
167 – Influenza (Including Avian Influenza and Swine Influenza) (2015) (34)
Dose-dependent neutralizing-antibody responses to vaccinia. (2004) (34)
Mercury levels in premature and low birth weight newborn infants after receipt of thimerosal-containing vaccines. (2009) (33)
Gain-of-Function Experiments on H7N9 (2013) (33)
Estimating probabilities of active brucellosis infection in Yellowstone bison through quantitative serology and tissue culture (2011) (33)
Directed selection of influenza virus produces antigenic variants that match circulating human virus isolates and escape from vaccine‐mediated immune protection (2016) (32)
Seasonal Influenza Can Poise Hosts for CD4 T-Cell Immunity to H7N9 Avian Influenza. (2015) (32)
Comparison of Serum Hemagglutinin and Neuraminidase Inhibition Antibodies After 2010–2011 Trivalent Inactivated Influenza Vaccination in Healthcare Personnel (2014) (31)
First-in-human randomized controlled trial of an oral, replicating adenovirus 26 vector vaccine for HIV-1 (2018) (31)
Low baseline antibody level to diphtheria is associated with poor response to conjugated pneumococcal vaccine in adults. (2001) (31)
Evaluation of the innate immune responses to influenza and live-attenuated influenza vaccine infection in primary differentiated human nasal epithelial cells. (2017) (29)
Radioimmunoassay for detection of the snow mountain agent of viral gastroenteritis (1986) (29)
Granulocyte macrophage colony-stimulating factor as an adjuvant for hepatitis B vaccination of healthy adults. (1999) (28)
Differential Effects of Pneumococcal Vaccines against Serotypes 6 A and 6 C In (2008) (28)
Prevalence of antibody to Bordetella pertussis antigens in serum specimens obtained from 1793 adolescents and adults. (2004) (27)
Development of an enzyme immunoassay for the Hawaii agent of viral gastroenteritis. (1988) (25)
Increase in IFNγ−IL-2+ Cells in Recent Human CD4 T Cell Responses to 2009 Pandemic H1N1 Influenza (2013) (25)
Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 18-49 years of age, naive to 23-valent pneumococcal polysaccharide vaccine. (2015) (25)
Rapid Licensure of a New, Inactivated Influenza Vaccine in the United States (2005) (25)
Simulating sterilization, vaccination, and test-and-remove as brucellosis control measures in bison (2011) (24)
Antigenic and immunogenic properties of recombinant hemagglutinin proteins from H1N1 A/Brisbane/59/07 and B/Florida/04/06 when produced in various protein expression systems. (2012) (24)
Abundance and specificity of influenza reactive circulating memory follicular helper and non‐follicular helper CD4 T cells in healthy adults (2015) (24)
Broad cross-reactive IgG responses elicited by adjuvanted vaccination with recombinant influenza hemagglutinin (rHA) in ferrets and mice (2018) (23)
Chronic inhibition of cyclooxygenase-2 attenuates antibody responses against vaccinia infection. (2010) (23)
Migratory and winter activity of bats in Yellowstone National Park (2016) (22)
Characterizing Emerging Canine H3 Influenza Viruses (2020) (22)
Characterisation of a wild-type influenza (A/H1N1) virus strain as an experimental challenge agent in humans (2015) (22)
Production of a monoclonal antibody against the Snow Mountain agent of gastroenteritis by in vitro immunization of murine spleen cells. (1988) (21)
B cell responses to H5 influenza HA in human subjects vaccinated with a drifted variant. (2010) (21)
Evaluation of a plasmid DNA-based anthrax vaccine in rabbits, nonhuman primates and healthy adults (2009) (20)
Prospects for broadly protective influenza vaccines. (2015) (20)
Overarching Immunodominance Patterns and Substantial Diversity in Specificity and Functionality in the Circulating Human Influenza A and B Virus–Specific CD4+ T-Cell Repertoire (2018) (19)
Intragenic suppression of a deletion mutation of the nonstructural gene of an influenza A virus (1991) (19)
Label-free, arrayed sensing of immune response to influenza antigens. (2011) (19)
Clinical and laboratory diagnosis of influenza virus infections. (2000) (19)
Heterovariant cross-reactive B-cell responses induced by the 2009 pandemic influenza virus A subtype H1N1 vaccine. (2013) (19)
Recombinant HA-based vaccine outperforms split and subunit vaccines in elicitation of influenza-specific CD4 T cells and CD4 T cell-dependent antibody responses in humans (2020) (18)
Incidence and viral aetiologies of acute respiratory illnesses (ARIs) in the United States: a population-based study (2016) (18)
Rethinking Influenza (2009) (18)
Use of live cold-adapted influenza A H1N1 and H3N2 virus vaccines in seropositive adults (1990) (18)
B-Cell Responses to Intramuscular Administration of a Bivalent Virus-Like Particle Human Norovirus Vaccine (2017) (17)
Humans and Ferrets with Prior H1N1 Influenza Virus Infections Do Not Exhibit Evidence of Original Antigenic Sin after Infection or Vaccination with the 2009 Pandemic H1N1 Influenza Virus (2014) (17)
Timing of parturition events in Yellowstone bison Bison bison: implications for bison conservation and brucellosis transmission risk to cattle (2010) (17)
Population Serologic Immunity to Human and Avian H2N2 Viruses in the United States and Hong Kong for Pandemic Risk Assessment (2018) (17)
Serum antibody responses of weanling mice and two-year-old children to pneumococcal-type 6A-protein conjugate vaccines of differing saccharide chain lengths. (1998) (17)
Monoclonal Antibody Responses after Recombinant Hemagglutinin Vaccine versus Subunit Inactivated Influenza Virus Vaccine: a Comparative Study (2019) (16)
Evidence that blunted CD4 T cells responses underlie deficient protective antibody responses to influenza vaccines in repeatedly vaccinated human subjects. (2019) (15)
INFLUENZA A AND B VIRUSES (1999) (15)
New Wisdom to Defy an Old Enemy: Summary from a scientific symposium at the 4th Influenza Vaccines for the World (IVW) 2012 Congress, 11 October, Valencia, Spain. (2013) (15)
Noroviruses and Other Caliciviruses (2010) (14)
Immune responses to vaccinia and influenza elicited during primary versus recent or distant secondary smallpox vaccination of adults. (2006) (14)
Production of influenza-stimulated tumor necrosis factor-alpha by monocytes following acute influenza infection in humans. (1999) (14)
A phase 2 study of the bivalent VLP norovirus vaccine candidate in older adults; impact of MPL adjuvant or a second dose. (2020) (14)
Viewpoint of a WHO Advisory Group Tasked to Consider Establishing a Closely-Monitored Challenge Model of COVID-19 in Healthy Volunteers (2020) (13)
Buildings provide vital habitat for little brown myotis ( Myotis lucifugus ) in a high‐elevation landscape (2019) (13)
A Live Attenuated Equine H3N8 Influenza Vaccine Is Highly Immunogenic and Efficacious in Mice and Ferrets (2014) (13)
Recombinant proteins produced in insect cells. (2009) (12)
Nucleotide sequence of the avian influenza A/Mallard/NY/6750/78 virus polymerase genes. (1989) (12)
Identification of HLA class II H5N1 hemagglutinin epitopes following subvirion influenza A (H5N1) vaccination. (2009) (11)
Immunogenicity, efficacy of inactivated/live virus seasonal and pandemic vaccines (2013) (11)
Antibody response to inactivated influenza A (H1N1) 2009 monovalent vaccine in patients with and without HIV. (2011) (11)
Vaccination with drifted variants of avian H5 hemagglutinin protein elicits a broadened antibody response that is protective against challenge with homologous or drifted live H5 influenza virus. (2011) (11)
Differences in the influenza-specific CD4 T cell immunodominance hierarchy and functional potential between children and young adults (2019) (11)
Chimeric Vaccines Against Japanese Encephalitis, Dengue, and West Nile (2004) (10)
Prospects for Broadly Protective Influenza Vaccines. (2015) (10)
Fever and progressive respiratory failure in three elderly family members. (2005) (10)
Chapter 14 Demography of Central Yellowstone Bison: Effects of Climate, Density, and Disease (2008) (10)
Stable emulsion (SE) alone is an effective adjuvant for a recombinant, baculovirus-expressed H5 influenza vaccine in healthy adults: A Phase 2 trial. (2017) (10)
Mercury in infants given vaccines containing thiomersal (2003) (9)
Continuous Readout versus Titer-Based Assays of Influenza Vaccine Trials: Sensitivity, Specificity, and False Discovery Rates (2019) (9)
Genetic and Antigenic Typing of Seasonal Influenza Virus Breakthrough Cases from a 2008-2009 Vaccine Efficacy Trial (2013) (8)
Evaluation of live attenuated cold-adapted influenza B/Yamagata/16/88 reassortant virus vaccine in healthy adults. (1993) (8)
A Single Dose of an Avian H3N8 Influenza Virus Vaccine Is Highly Immunogenic and Efficacious against a Recently Emerged Seal Influenza Virus in Mice and Ferrets (2015) (8)
Gain-of-function experiments on H7N9. (2013) (7)
Recombinant HA-based vaccine outperforms split and subunit vaccines in elicitation of influenza-specific CD4 T cells and CD4 T cell-dependent antibody responses in humans (2020) (7)
Improved Specificity and False Discovery Rates for Multiplex Analysis of Changes in Strain-Specific Anti-Influenza IgG (2019) (7)
Integrating ecology with management to control wildlife brucellosis. (2013) (7)
Characterization of the attenuating M and NP gene segments of the avian influenza A/Mallard/78 virus during in vitro production of avian-human reassortant vaccine viruses and after replication in humans and primates. (1991) (7)
Maintenance of brucellosis in Yellowstone bison: linking seasonal food resources, host–pathogen interaction, and life-history trade-offs (2015) (7)
Genes Involved in the Restriction of Replication of Avian Influenza A Viruses in Primates (1990) (7)
Mercury in infants given vaccines containing thiomersal. Authors' reply (2003) (6)
Safety and Immunogenicity of a Recombinant Influenza Vaccine: A Randomized Trial (2018) (6)
Broadly-reactive IgG responses to heterologous H5 prime-boost influenza vaccination are shaped by antigenic relatedness to priming strains (2021) (6)
Viral infections of the respiratory tract: prevention and treatment. (1994) (5)
Divergent H 7 Immunogens Offer Protection from H 7 N 9 Virus Challenge (2014) (5)
Allonursing and Cooperative Birthing Behavior in Yellowstone Bison, Bison bison (2008) (5)
What Happens Next Depends on What Happened First. (2018) (5)
Viral Infections (2015) (5)
Correction to Pressman et al. (2005). (2005) (5)
Bovine brucellosis in wildlife: using adaptive management to improve understanding, technology and suppression. (2013) (5)
Expanding the options for confronting pandemic influenza. (2014) (5)
Improving pandemic preparedness through better, faster influenza vaccines (2021) (5)
Flu Vaccine-Too Much of a Good Thing? (2017) (4)
Use of bacteriophage particles displaying influenza virus hemagglutinin for the detection of hemagglutination-inhibition antibodies. (2014) (4)
Can the rolling cross-sectional survey design be used to estimate the effectiveness of influenza vaccines? (2014) (4)
THE BIOLOGY AND MANAGEMENT OF BRUCELLOSIS IN YELLOWSTONE BISON (2012) (4)
Adjuvanted recombinant hemagglutinin H7 vaccine to highly pathogenic influenza A(H7N9) elicits high and sustained antibody responses in healthy adults (2021) (4)
Plains Spadefoot, Spea bombifrons, Confirmed in Yellowstone National Park (2015) (3)
178 – Noroviruses and Sapoviruses (Caliciviruses) (2015) (3)
Antiviral treatment and prophylaxis of influenza virus in children. (2009) (3)
Influenza: New options for prevention and treatment (2002) (3)
Mercury in vaccines and potential conflicts of interest (2004) (3)
Transient decrease in human peripheral blood myeloid dendritic cells following influenza vaccination correlates with induction of serum antibody (2014) (3)
Book Review Cold Wars: The Fight against the Common Cold By David Tyrrell and Michael Fielder. 253 pp., illustrated. New York, Oxford University Press, 2002. $24.95. 0-19-263285-X (2004) (3)
Avian Influenza: Exploring All the Avenues (2006) (3)
INFECTIOUS DISEASES OF THE LUNGS (2016) (3)
Gaps in Serologic Immunity against Contemporary Swine-Origin Influenza A Viruses among Healthy Individuals in the United States (2021) (2)
Social networks based on frequency of roost cohabitation do not reflect association rates of Myotis lucifugus within their roosts (2021) (2)
Effective Immune Response In Patients Who Have Hematologic Malignancies After Vaccination with Inactivated Influenza A (H1N1) 2009 Monovalent Vaccine (2010) (2)
Safety and Immunogenicity of a Baculovirus- Expressed Hemagglutinin Influenza Vaccine (2016) (2)
1074 SAFETY AND IMMUNOGENICITY OF A LIVE ATTENUATED RHESUS MONKEY ROTAVIRUS VACCINE (1985) (2)
Editorial commentary: influenza vaccine: glass half full or half empty? (2013) (2)
Serological evidence for historical and present-day exposure of North American bison to Mycoplasma bovis (2021) (2)
Seasonal Foraging Strategies of Migrant and Non-Migrant Pronghorn In Yellowstone National Park (2017) (2)
Influenza Challenge and the Challenge of Drug Development. (2018) (2)
Adjuvanted recombinant hemagglutinin H7 vaccine to highly pathogenic influenza A(H7N9) elicits high and sustained antibody responses in healthy adults (2021) (1)
Cross-reactive anti-hemagglutinin (HA) IgG responses are shaped by previous long-interval monovalent H5 vaccination and highly correlated with HA antigenic distance (2020) (1)
179 – Astroviruses and Picobirnaviruses (2015) (1)
Enhanced Potency and Durability of Antibody Response to Seasonal Trivalent Inactivated Influenza Vaccine (TIV) Combined with a Novel Water-in-Oil Adjuvant System at Reduced Hemagglutinin (HA) Doses (2017) (1)
Broadly Reactive IgG Responses to Heterologous H5 Prime-Boost Influenza Vaccination Are Shaped by Antigenic Relatedness to Priming Strains (2021) (1)
History of Live, Attenuated Influenza Vaccine. (2020) (1)
14 Balancing Bison Conservation and Risk Management of the Non- Native Disease Brucellosis (2013) (1)
Response and Hemagglutinin Stalk-Reactive Antibody Production in Different Age Cohorts following 2009 H 1 N 1 Influenza Virus Vaccination (2018) (1)
The Helmet Protects the Aviator's Head--or Does It, (1977) (0)
Characterizing Emerging Canine H3 Influenza Viruses. (2020) (0)
Individuals-Specific Memory B Cells in Malaria-Naive Plasmodium falciparum Acquisition of The TLR 9 Ligand CpG Promotes the Martin and (2009) (0)
Efficacy of Influenza Vaccination in (2017) (0)
Reduction in vomiting associated with norovirus vaccination in a live norovirus human challenge study (2014) (0)
Contributors (2012) (0)
Seasonal In fl uenza Can Poise Hosts for CD 4 T-Cell Immunity to H 7 N 9 Avian In fl uenza (2015) (0)
Vaccine Prepandemic Priming on CD 4 + T-Cell Responses (2015) (0)
Characterisation of a wild-type influenza (A/H1N1) virus strain as an experimental challenge agent in humans (2015) (0)
The Invisible Hand of Disease (2007) (0)
Randomized, Double-Blind Controlled Phase 3 Trial Comparing the Immunogenicity of High-Dose and Standard-Dose Inﬂuenza Vaccine in Adults 65 Years of Age and Older (2009) (0)
Natural H3N2 influenza A infection in humans expands memory B cells specific for the hemagglutinin stalk domain (2016) (0)
Prospects for Vaccines to Prevent Norovirus (2016) (0)
Editorial Commentary: Is Prepandemic Vaccination a Wise Investment? (2015) (0)
A Highly Potent and Broadly Neutralizing H1 Influenza-Specific Human Monoclonal Antibody (2018) (0)
In ﬂ uenza Vaccine: Glass Half Full or Half Empty? (2013) (0)
Introduction (2004) (0)
Efficacy of Trivalent Live Attenuated Intranasal Influenza Vaccine against Monovalent Influenza H1N1 Challenge in Children (1999) (0)
Population sizes and activity patterns of little brown myotis in Yellowstone National Park (2022) (0)
Clinical development of pandemic influenza vaccines. (2008) (0)
Pittsburgh Mind-Body Center Cold Study (PMBC) (2014) (0)
EVALUATION OF A PENTAVALENT CONJUGATED PNEUMOCOCCAL VACCINE IN TODDLERS.▴ 1077 (1996) (0)
High-Af fi nity H 7 Head and Stalk Domain – Speci fi c Antibody Responses to an Inactivated In fl uenza H 7 N 7 Vaccine After Priming With Live Attenuated In fl uenza Vaccine (2015) (0)
Norovirus Vaccine Development—Current Status (2015) (0)
Infection-induced proin X ammatory cytokines are associated with decreases in positive a V ect , but not increases in negative a V ect (2006) (0)
Evaluation of neuraminidase inhibitors in the human experimental infection model (2001) (0)
INFLUENZA VACCINATION IN HIV-INFECTED PERSONS: (1999) (0)
Cold weather aviation psychology: a case report. (1977) (0)
373 – Adenovirus Diseases (2012) (0)
Characterization oftheSnowMountain Agentof Viral Gastroenteritis (1986) (0)
Respiratory Viruses (2002) (0)
Maximum Likelihood Estimation of Titer via a Power Family of Four-Parameter Logistic Model (2018) (0)
Running Title: Mathematical Modeling for Influenza A Virus Infection 1 2 Title: Simulation and Prediction of the Adaptive Immune Response to Influenza A Virus 3 Infection 4 (2009) (0)
Differences in the influenza-specific CD4 T cell immunodominance hierarchy and functional potential between children and young adults (2019) (0)
Baseline and comparative neuropsychological data on U.S. Army aviators. (1986) (0)
Corrigendum to “Use of bacteriophage particles displaying influenza virus hemagglutinin for the detection of hemagglutination-inhibition antibodies” [J. Virol. Methods 197 (2014) 47–50)] (2014) (0)
In fl uenza Vaccine : Glass Half Full or Half Empty ? (2013) (0)
Vaccines in the Immunocompromised Hosts (2018) (0)
Effect of In fl uenza A ( H 5 N 1 ) Vaccine Prepandemic Priming on CD 4 + T-Cell Responses (2015) (0)
988. Effectiveness of Seasonal Influenza Vaccines Against Influenza A(H3N2) Illness Among Children Aged <18 Years, US Flu VE Network, 2010–2018 (2018) (0)
Contributors (2015) (0)
Date of Patent : * Sep . 12 , 2000 PATHOGEN PROPAGATION IN CULTURED THREE-DIMENSIONAL TISSUE (2007) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With John. J. Treanor?

John. J. Treanor is affiliated with the following schools:

Eastern Virginia Medical School
University of Pittsburgh
University of Rochester

John. J. Treanor's Academic­Influence.com Rankings

Why Is John. J. Treanor Influential?

John. J. Treanor's Published Works

Published Works

What Schools Are Affiliated With John. J. Treanor?

John. J. Treanor's AcademicInfluence.com Rankings